Leflunomide for Cats and Dogs: Uses and Safety
Comprehensive guide to leflunomide: an immunomodulating medication for treating immune-mediated conditions in pets.
What is Leflunomide?
Leflunomide is an immunomodulating agent used to treat certain immune-mediated conditions in cats and dogs. This medication works by suppressing the immune system and reducing autoimmune responses that can harm your pet’s health. Leflunomide is classified as a synthetic isoxazole prodrug that becomes active after being metabolized in the intestinal mucosa and liver to its active metabolite, A77 1726 (also known as teriflunomide). The medication has been used in human medicine for many years, primarily for rheumatoid arthritis, psoriatic arthritis, and transplantation medicine, before becoming increasingly popular in veterinary practice.
Off-Label Use in Veterinary Medicine
Leflunomide is used off-label (extra-label) in veterinary medicine. This means the drug is being used in a way that has not been reviewed or approved by the U.S. Food and Drug Administration (FDA) or Health Canada. Many drugs are commonly prescribed for off-label use in veterinary medicine because they have proven effective for treating conditions in pets that are not specifically approved on the drug’s label. When your veterinarian prescribes leflunomide off-label, it is important to follow their directions and cautions carefully, as they may be significantly different from those on the original pharmaceutical label.
Conditions Treated with Leflunomide
Leflunomide has become a valuable treatment option for various immune-mediated and inflammatory conditions in dogs and cats. The primary conditions treated with this medication include:
- Autoimmune Hemolytic Anemia (AIHA) or Immune-Mediated Hemolytic Anemia (IMHA)
- Immune Thrombocytopenia (ITP)
- Immune-Mediated Polyarthritis (IMPA)
- Rheumatoid Arthritis
- Granulomatous Meningoencephalitis (GME)
- Immune-Mediated Conditions of the Central Nervous System
- Inflammatory Bowel Disease (IBD)
In dogs, leflunomide has been used as a treatment for AIHA or ITP, either as a first-line drug or for cases that are refractory to conventional therapies. Additionally, veterinarians commonly use leflunomide combined with prednisone as initial therapy for immune-mediated polyarthritis, rheumatoid arthritis, and GME. When used in combination with other drugs as an initial treatment for GME, leflunomide has shown great promise in increasing longevity and preventing relapses.
How Leflunomide Works
Leflunomide functions as an immunomodulator by affecting how the immune system operates. The medication works by inhibiting the production of T-cells and B-cells, which are critical components of the immune response. More specifically, leflunomide inhibits the synthesis of pyrimidine, thereby inhibiting lymphocyte proliferation and reducing autoimmune T-cell proliferation and autoantibody production by B cells. This mechanism of action makes it particularly effective for treating conditions where the body’s defense system is not functioning properly and may be attacking itself.
One significant advantage of using leflunomide as part of initial treatment in immune-mediated diseases is that it allows prednisone to be decreased more quickly in dogs that are sensitive to corticosteroid side effects. This can be particularly beneficial for pets that experience adverse reactions to long-term prednisone use.
Dosing Guidelines
Proper dosing is crucial for the safe and effective use of leflunomide in veterinary patients. Dogs are considerably more sensitive to leflunomide than human patients, so significantly lower doses are used in canine patients. Since the gastrointestinal tract metabolizes leflunomide to its active metabolite, severe gastrointestinal side effects can occur at higher doses. However, the canine lymphocyte is much more sensitive than the human lymphocyte to the effects of the active metabolite, allowing lower doses to still achieve therapeutic concentrations while avoiding GI side effects.
Current recommended starting dosages in dogs are 2-4 mg/kg once daily. In cats, the typical dose is 2 mg/kg once daily (approximately 10 mg per cat on average) for several days, then usually decreased to every other day. The drug reaches steady state fairly rapidly in approximately 4 days.
More recent clinical studies have suggested that a lower starting dose of 2 mg/kg/day may be safer and of similar efficacy compared to previously published higher doses of 3-4 mg/kg/day. The median starting dose used in clinical practice was found to be 1.7 mg/kg/day, with a range of 0.8 to 4.3 mg/kg/day, indicating that lower doses are becoming more common in veterinary practice.
Monitoring and Blood Serum Levels
Ideally, a trough blood serum level should be measured 10-14 days after starting leflunomide to ensure appropriate therapeutic concentrations. A trough level is obtained 22-24 hours after administration of the medication. Dosage adjustments may be made based on these measured values and your pet’s clinical response to treatment.
Currently, blood samples are sent to specialized clinical pharmacology laboratories for measurement of leflunomide levels. The reported value represents the amount of detected active metabolite (A77 1726). Auburn University lists the therapeutic range of the active metabolite as 20-25 mcg/ml; however, the University of California Davis, which originally studied this drug’s clinical use in dogs, suggests that the therapeutic range is actually 20-40 mcg/ml. Clinical experience over recent years supports the higher therapeutic range of 20-40 mcg/ml.
Administration Instructions
Leflunomide is typically administered once daily and can be given with or without food. However, if your pet experiences nausea after taking leflunomide, it is advisable to administer subsequent doses with food to mitigate this gastrointestinal upset. Your veterinarian will provide specific instructions based on your individual pet’s needs and response to the medication.
Side Effects and Safety Considerations
While leflunomide is generally well-tolerated in veterinary patients, certain side effects and safety considerations should be understood. The most commonly reported side effects include gastrointestinal symptoms such as nausea, lethargy, vomiting, and diarrhea. Other potential symptoms include pale gums, which may indicate anemia or other systemic effects.
A recent retrospective study examining leflunomide safety found that out of 31 dogs with non-hematologic diseases that had baseline and post-treatment complete blood counts (CBCs) performed, two dogs developed mild thrombocytopenia (low platelet count) when CBCs were performed 2 weeks after starting treatment. Both dogs had their platelets normalize following a 50% dose reduction. For dogs with a second post-treatment CBC performed, none had evidence of hematologic disturbances. Furthermore, anemia or neutropenia was not noted in any dogs in the study.
The study demonstrated that leflunomide appears to be another effective option as treatment for a variety of immune-mediated conditions in dogs, with an overall positive response rate of over 70%. The lower starting dose of 2 mg/kg/day of leflunomide may be safer and of similar efficacy compared to previously published higher doses.
Combination Therapy Approach
In clinical practice, leflunomide is often used as adjunctive therapy in combination with other medications. Most commonly, leflunomide is added to prednisone therapy to enhance symptom control and potentially reduce the necessary dosage of prednisone. It may take up to a month to assess the effectiveness of leflunomide for your pet, so patience is important when starting this medication.
The use of leflunomide combined with prednisone as initial therapy for immune-mediated polyarthritis, rheumatoid arthritis, and GME provides veterinarians with a more powerful treatment approach. This combination allows for more rapid control of symptoms while potentially reducing corticosteroid-related side effects over time.
When to Contact Your Veterinarian
If your pet is experiencing non-specific symptoms such as nausea, lethargy, vomiting, diarrhea, or pale gums, you should take your pet to your local veterinarian for examination. In cases where a pet has an autoimmune disorder, it can be especially difficult to determine the cause of symptoms without comprehensive blood tests. If your pet is diagnosed with an autoimmune disorder such as immune-mediated hemolytic anemia, irritable bowel disease, or histiocytosis, your veterinarian may prescribe leflunomide.
Frequently Asked Questions
Q: Is leflunomide approved by the FDA for veterinary use?
A: No, leflunomide is used off-label in veterinary medicine, meaning it has not been reviewed or approved by the FDA or Health Canada for use in cats and dogs. However, it is commonly prescribed by veterinarians under the prescribing cascade when conventional treatments have been ineffective.
Q: How long does it take for leflunomide to work?
A: It may take up to a month to assess the effectiveness of leflunomide for your pet. The drug reaches steady state in approximately 4 days, but clinical response to treatment may take longer to manifest.
Q: Can leflunomide be used in cats?
A: Yes, leflunomide can be used in cats. The typical dose is 2 mg/kg once daily (approximately 10 mg per cat on average) for several days, then usually decreased to every other day.
Q: What should I do if my pet experiences gastrointestinal side effects?
A: If your pet experiences nausea or other gastrointestinal upset after taking leflunomide, you can try administering the medication with food. If symptoms persist, contact your veterinarian, as a dose adjustment may be necessary.
Q: Why is blood monitoring important when using leflunomide?
A: Blood serum level monitoring ensures that your pet is receiving a therapeutic dose of the active metabolite. This helps your veterinarian optimize the dosage and ensure the medication is working effectively while minimizing the risk of side effects.
Q: Can leflunomide be used as a first-line treatment?
A: Yes, leflunomide can be used as a first-line treatment for certain immune-mediated conditions, particularly when combined with prednisone. It is also used for refractory cases where conventional treatments have been ineffective.
Q: What is the difference between leflunomide and prednisone?
A: Leflunomide is an immunomodulator that specifically inhibits lymphocyte proliferation and autoimmune responses. Prednisone is a corticosteroid that broadly suppresses immune function and reduces inflammation. Using them together allows for lower doses of prednisone and potentially fewer corticosteroid side effects.
References
- The Benefits of Leflunomide — MSPCA-Angell Animal Medical Center. 2025. https://www.mspca.org/angell_services/the-benefits-of-leflunomide/
- Leflunomide For Dogs and Cats — Avrio Pharmacy. 2025. https://avriorx.com/leflunomide-for-dogs-and-cats/
- Leflunomide for Immune Disorders in Pets — Remedy SF Veterinary. 2025. https://www.remedyvets.com/leflunomide
- Safety and Efficacy of Leflunomide in Dogs — VETgirl Veterinary Continuing Education. 2025. https://vetgirlontherun.com/podcasts/safety-and-efficacy-of-leflunomide-dogs-vetgirl-veterinary-ce-podcasts/
- Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy — C.R. Gregory et al., Transplant Proceedings, 1998. https://pubmed.ncbi.nlm.nih.gov/9865328/
- Leflunomide — VCA Animal Hospitals. 2025. https://vcahospitals.com/know-your-pet/leflunomide
Similar Articles
Read full bio of medha deb
